Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





Income Statement
Balance Sheet
Cash Flow Statement

Common Size IS
Op Efficiency
Credit Analysis

Quince Therapeutics, Inc. (CRTX)

Income Statement

Standardized | As Reported Annual | Quarterly | TTM
 
In millions, except per share itemsDec-31-22Dec-31-21Dec-31-20Dec-31-19Dec-31-18Dec-31-17
   10-K10-K10-K10-K10-KS-1/A
Revenues  0.00.00.00.00.09.1
            Revenue growth      -100.0% 
Cost of goods sold  0.00.00.00.00.010.4
Gross profit  0.00.00.00.00.0-1.3
            Gross margin       -14.0%
Selling, general and administrative   [+]26.029.517.69.02.01.3
Research and development  25.260.861.330.210.1 
Other operating expenses       7.8
EBITDA   [+]-51.0-90.0-78.6-39.0-12.1-10.3
            EBITDA margin       -113.5%
Depreciation and amortization  0.20.30.30.20.10.0
EBIT   [+]-51.2-90.3-78.9-39.2-12.1-10.4
            EBIT margin       -114.0%
Non-recurring items   [+]0.8     
Interest income, net   [+]1.10.62.02.2-0.2-1.6
Other income (expense), net   [+]-1.0-0.2  -0.2-0.2
Pre-tax income  -51.9-89.9-76.8-37.0-12.5-12.2
Income taxes  0.30.00.00.00.00.0
            Tax rate   0.0%0.0%0.0%0.0%0.0%
Net income  -51.90.0-76.8-37.0-12.5-12.2
            Net margin       -134.5%
   
Basic EPS   [+]($1.55)$0.00($2.63)($1.94)($3.71)($3.70)
Diluted EPS   [+]($1.55)$0.00($2.63)($1.94)($3.71)($3.70)
   
Shares outstanding (basic)   [+]33.529.729.219.03.43.3
Shares outstanding (diluted)   [+]33.529.729.219.03.43.3
   
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.  

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy